Granted Patent
B2
US 12,552,862 · App. 18/045,109 · Granted Feb 17, 2026
Oligonucleotides for reduction of PD-L1 expression
Inventors:
Lykke Pedersen (Horsholm, DK); Hassan Javanbakht (Basel, CH); Malene Jackerott (Horsholm, DK); Soren Ottosen (Horsholm, DK); Souphalone Luangsay (Basel, CH)
Assignee:
HOFFMANN-LA ROCHE INC.
C07K16/28A61K38/1709A61K39/39A61K39/39558C12N15/1138A61K2039/505A61K2039/55516A61K2039/572A61K45/06C07K2317/70C12N2310/11C12N2310/315C12N2310/3231C12N2310/341C12N2310/346C12N2310/351G01N2800/26Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
Claims (11)
1 . An antisense oligonucleotide conjugate of formula GN2-C6 o c o a o CTAattgtagtagtaCTC(SEQ ID NO. 466), wherein C6 represents an amino alkyl group with 6 carbons, capital letters represent beta-D-oxy LNA nucleosides, lowercase letters represent DNA nucleosides, all LNA C are 5-methyl cytosine, subscript o represents a phosphodiester nucleoside linkage and unless otherwise indicated, all internucleoside linkages are phosphorothioate internucleoside linkages, and wherein GN2 represents the trivalent GalNAc cluster of formula
further wherein the wavy line illustrates the site of conjugation of the cluster to the C6 amino alkyl group.
2 . A pharmaceutical composition comprising the antisense oligonucleotide conjugate of claim 1 and a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant.
3 . The pharmaceutical composition according to claim 2 wherein the pharmaceutically acceptable diluent is sterile phosphate buffered saline.
4 . The pharmaceutical composition according to claim 2 wherein the pharmaceutically acceptable salt is sodium or potassium.
5 . An in vivo or in vitro method for modulating PD-LI expression in a target cell which is expressing PD-LI, the method comprising administering the antisense oligonucleotide conjugate of claim 1 in an effective amount to the cell.
6 . A method for treating or preventing a disease comprising administering a therapeutically or prophylactically effective amount of the pharmaceutical composition of claim 2 to a subject suffering from or susceptible to the disease.
7 . A method for treating or preventing HBV infection comprising administering a therapeutically or prophylactically effective amount of the pharmaceutical composition of claim 2 to a subject suffering from or susceptible to HBV infection.
8 . A pharmaceutically acceptable salt of the antisense oligonucleotide conjugate of claim 1 .
9 . A pharmaceutically acceptable sodium salt of the antisense oligonucleotide conjugate of claim 1 .
10 . A pharmaceutically acceptable potassium salt of the antisense oligonucleotide conjugate of claim 1 .
Priority Claims (1)
EP 16160149
· Mar 14, 2016
· regional
Continuity (5)
References Cited (226)
US 4587044A
· Miller et al.
· 1986
[cited by applicant]
US 4667025A
· Miyoshi et al.
· 1987
[cited by applicant]
US 4948882A
· Ruth
· 1990
[cited by applicant]
US 5112963A
· Pieles et al.
· 1992
[cited by applicant]
US 5245022A
· Weis et al.
· 1993
[cited by applicant]
US 5254469A
· Warren et al.
· 1993
[cited by applicant]
US 5391723A
· Priest
· 1995
[cited by applicant]
US 5486603A
· Buhr
· 1996
[cited by applicant]
US 5510475A
· Agrawal et al.
· 1996
[cited by applicant]
US 5512667A
· Reed et al.
· 1996
[cited by applicant]
US 5525465A
· Haralambidis et al.
· 1996
[cited by applicant]
US 5541313A
· Ruth
· 1996
[cited by applicant]
US 5545730A
· Urdea et al.
· 1996
[cited by applicant]
US 5552538A
· Urdea et al.
· 1996
[cited by applicant]
US 5574142A
· Meyer et al.
· 1996
[cited by applicant]
US 5580731A
· Chang et al.
· 1996
[cited by applicant]
US 5608046A
· Cook et al.
· 1997
[cited by applicant]
US 5684142A
· Mishra et al.
· 1997
[cited by applicant]
US 5770716A
· Khan et al.
· 1998
[cited by applicant]
US 5885968A
· Biessen et al.
· 1999
[cited by applicant]
US 5994517A
· Ts et al.
· 1999
[cited by applicant]
US 6096875A
· Khan et al.
· 2000
[cited by applicant]
US 6335432B1
· Segev
· 2002
[cited by applicant]
US 6335437B1
· Manoharan
· 2002
[cited by applicant]
US 8507663B2
· Defougerolles et al.
· 2013
[cited by applicant]
US 20120122801A1
· Platenburg
· 2012
[cited by applicant]
US 20150232836A1
· Krieg et al.
· 2015
[cited by applicant]
US 20170283496A1
· Pedersen et al.
· 2017
[cited by applicant]
CN 101084438A
· 2007
[cited by applicant]
CN 104479018
· 2015
[cited by applicant]
CN 104583401A
· 2015
[cited by applicant]
CN 104955952A
· 2015
[cited by applicant]
CN 108779465
· 2018
[cited by applicant]
EP 1495769A1
· 2005
[cited by applicant]
EP 1537878A1
· 2005
[cited by applicant]
EP 2361921A2
· 2011
[cited by applicant]
EP 2404997A1
· 2012
[cited by applicant]
EP 2734208B1
· 2017
[cited by applicant]
EP 3377510B1
· 2020
[cited by applicant]
EP 3430141B1
· 2020
[cited by applicant]
JP 2008515442A
· 2008
[cited by applicant]
JP 2008543774A
· 2008
[cited by applicant]
JP 2012510619A
· 2012
[cited by applicant]
JP 2013523162A
· 2013
[cited by applicant]
JP 2014210793A
· 2014
[cited by applicant]
JP 20210212541
· 2021
[cited by applicant]
JP 7447073
· 2024
[cited by applicant]
RU 2123528C1
· 1998
[cited by applicant]
WO 9307883A1
· 1993
[cited by applicant]
WO 9611205A1
· 1996
[cited by applicant]
WO 9839352A1
· 1998
[cited by applicant]
WO 9852614A2
· 1998
[cited by applicant]
WO 9914226A2
· 1999
[cited by applicant]
WO 9965925A1
· 1999
[cited by applicant]
WO 0047599A1
· 2000
[cited by applicant]
WO 0066604A2
· 2000
[cited by applicant]
WO 0123613A1
· 2001
[cited by applicant]
WO 2004046160A2
· 2004
[cited by applicant]
WO 2005007855A2
· 2005
[cited by applicant]
WO 2005014806A2
· 2005
[cited by applicant]
WO 2006042237A2
· 2006
[cited by applicant]
WO 2006133396A2
· 2006
[cited by applicant]
WO 2007031091A2
· 2007
[cited by applicant]
WO 2007084865A2
· 2007
[cited by applicant]
WO 2007090071A2
· 2007
[cited by applicant]
WO 2007134181A2
· 2007
[cited by applicant]
WO 2007146511A2
· 2007
[cited by applicant]
WO 2008113832A2
· 2008
[cited by applicant]
WO 2008150729A2
· 2008
[cited by applicant]
WO 2008154401A2
· 2008
[cited by applicant]
WO 2009006478A2
· 2009
[cited by applicant]
WO 2009067647A1
· 2009
[cited by applicant]
WO 2009090182A1
· 2009
[cited by applicant]
WO 2009124238A1
· 2009
[cited by applicant]
WO 2009126933A2
· 2009
[cited by applicant]
WO 2010036698A1
· 2010
[cited by applicant]
WO 2010063011A2
· 2010
[cited by applicant]
WO 2010077578A1
· 2010
[cited by applicant]
WO WO2010077634
· 2010
[cited by applicant]
WO 2010101249A1
· 2010
[cited by applicant]
WO 2010129799A2
· 2010
[cited by applicant]
WO 2011017521A2
· 2011
[cited by applicant]
WO 2011127180A1
· 2011
[cited by applicant]
WO WO2011143762
· 2011
[cited by applicant]
WO 2011156202A1
· 2011
[cited by applicant]
WO 2012024170A2
· 2012
[cited by applicant]
WO 2012055362A1
· 2012
[cited by applicant]
WO 2012083046A2
· 2012
[cited by applicant]
WO 2012089352A1
· 2012
[cited by applicant]
WO 2012145697A1
· 2012
[cited by applicant]
WO 2013003520A1
· 2013
[cited by applicant]
WO 2013012758A1
· 2013
[cited by applicant]
WO 2013033230A1
· 2013
[cited by applicant]
WO 2013036868A1
· 2013
[cited by applicant]
WO 2013049307A2
· 2013
[cited by applicant]
WO 2013154798A1
· 2013
[cited by applicant]
WO 2013159109A1
· 2013
[cited by applicant]
WO 2013173598A1
· 2013
[cited by applicant]
WO 2014076195A1
· 2014
[cited by applicant]
WO 2014076196A1
· 2014
[cited by applicant]
WO 2014083178A1
· 2014
[cited by applicant]
WO 2014118267A1
· 2014
[cited by applicant]
WO 2014118272A1
· 2014
[cited by applicant]
WO 2014179620A1
· 2014
[cited by applicant]
WO 2014179629A2
· 2014
[cited by applicant]
WO 2014207232A1
· 2014
[cited by applicant]
WO 2015114146A1
· 2015
[cited by applicant]
WO 2016025647A1
· 2016
[cited by applicant]
WO 2016055601A1
· 2016
[cited by applicant]
WO 2016138278A2
· 2016
[cited by applicant]
WO 2016180784A1
· 2016
[cited by applicant]
WO 2017055423A1
· 2017
[cited by applicant]
WO 2017084987A1
· 2017
[cited by applicant]
WO 2017100587A1
· 2017
[cited by applicant]
WO 2017157899A
· 2018
[cited by applicant]
Langer, R, “New Methods of Drug Delivery,” Science, 1990, vol. 249, pp. 1527-1533, 7 pages.
[cited by applicant]
Mangos et al., “Efficient RNase H-directed cleavage of RNA promoted by antisense DNA or 2′F-ANA constructs containing acyclic nucleotide inserts,” J. Am. Chem. Soc., Jan. 22, 2003, 125(3):654-661.
[cited by applicant]
Manoharan, “Oligonucleotide Conjugates as Potential Antisense Drugs with Improved Uptake, Biodistribution, Targeted Delivery, and Mechanism of Action,” Antisense and Nucleic Acid Drug Development, Jul. 8, 2004, 12(2):10…
[cited by applicant]
Krieg et al., “Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible,” Antisense Research and Development, 1991, 1(2):161-171.
[cited by applicant]
Jobst et al., “Selective sugar binding to the carbohydrate recognition domains of the rat hepatic and macrophage asialoglycoprotein receptors,” J Biol Chem, Mar. 22, 1996, 271(12):6686-6693.
[cited by applicant]
Japanese Patent Office, “Office Action,” issued in connection with Japanese Patent Application No. 2021212541 dated Feb. 28, 2023 (7 pages) (4 pages of English Translation and 3 pages of Original Document).
[cited by applicant]
Holdgate, GA et al., “Measurements of binding thermodynamics in drug discovery,” Drug Discovery Today, 2005, vol. 10, No. 22, pp. 1543-1550, 8 pages.
[cited by applicant]
Mazanet, M. M., et al., “B7-H1 Is Expressed by Human Endothelial Cells and Suppresses T Cell Cytokine Synthesis”, The Journal of Immunology, vol. 169, No. 7, 2002, pp. 3581-3588.
[cited by applicant]
McTigue PM et al. “Sequence-Dependent Thermodynamic Parameters for Locked Nucleic Acid (LNA)-DNA Duplex Formation,” Biochemistry, 2004, vol. 43(18), pp. 5388-5405, 18 pages.
[cited by applicant]
Mergny, JL et al., “Analysis of Thermal Melting Curves,” Oligonucleotides, 2003, vol. 13, pp. 515-537, 23 pages.
[cited by applicant]
Hirao, I. et al., “Natural versus Artificial Creation of Base Pairs in DNA: Origin of Nucleobases from the Perspectives of Unnatural Base Pair Studies,” Accounts of Chemical Research, 2012, vol. 45, No. 12, pp. 2055-206…
[cited by applicant]
Mitsuoka et al., “A bridged nucleic acid, 2′,4′-BNA COC: synthesis of fully modified oligonucleotides bearing thymine, 5-methylcytosine, adenine and guanine 2′,4′-BNA COC monomers and RNA-selective nucleic-acid recognit…
[cited by applicant]
Hansen, LD et al., Entropy Titration. A Calorimetric Method for the Determination of .DELTA.G.degree.(K), .DELTA.H.degree. and DELTA.S.degree. , Chemical Communications, 1965, pp. 36-38, 3 pages.
[cited by applicant]
Morita K et al., “2′-O,4′-C-Ethylene-Bridged Nucleic Acids (ENA): Highly Nuclease-Resistant and Thermodynamically Stable Oligonucleotides for Antisense Drug,” Bioorganic & Medicinal Chemistry Letters, 2002, vol. 12, pp.…
[cited by applicant]
Nayersina R et al., “HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection,” Journal of Immunology, (1993), vol. 150(10), pp. 4659-4671, 1…
[cited by applicant]
Gutierrez et al. “Regulation of Trypanosoma cmzi-induced myocarditis by programmed death cell receptor I,” Infectimmun, May 2011, 79(5):1873-1881.
[cited by applicant]
Freier et al., “The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes,” Nucl. Acid Res., Nov. 15, 1997, 25(22):4429-4443.
[cited by applicant]
Flutter, K et al., “Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4′C.:-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer,” Molecular B…
[cited by applicant]
European Patent Office, “Office Action,” issued in connection with European Patent Application No. 20201780.2 dated Sep. 27, 2021 (4 pages).
[cited by applicant]
European Patent Office, “Office Action,” issued in connection with European Patent Application No. 17710874.3 dated Jan. 22, 2020 (5 pages).
[cited by applicant]
Official Letter issued in Colombia Patent Application No. NC2020/0010348 on May 3, 2021, 7 pgs.
[cited by applicant]
Pajot A et al., “A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice,” Eur Journal of Immunology, 2004, vol. 34, pp. 3060-3069, 10 pages.
[cited by applicant]
European Patent Office, “European search report,” issued in connection with European Patent Application No. 20201780.2 dated Jan. 25, 2021 (8 pages).
[cited by applicant]
Duff, et al., “Intrabody tissue-specific delivery of antisense conjugates in animals: ligand-linker-antisense oligomer conjugates,” Methods Enzvmol, Dec. 31, 2000, 313:297-321.
[cited by applicant]
Deleavey, GE et al., “Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing,” Chemistry and Biology, 2012, vol. 19(8), pp. 937-954, 18 pages.
[cited by applicant]
Claims of Chilean Patent Application No. 20200865, filed Jun. 10, 2020, 5 pgs.
[cited by applicant]
Rukov et al., “Dissecting the target specificity ofRNase H recruiting oligonucleotides using massively parallel reporter analysis of short RNA motifs,” Nucl. Acids Res, Sep. 30, 2015, 43(17):8476-8487.
[cited by applicant]
Chilean Patent Application No. 20200865, filed Mar. 31, 2020, 685 pgs.
[cited by applicant]
Santa Lucia, JJr., “A unified view of polymer, dumbbell, and oligonucleotide DNA nearest-neighborthermodynamics,” Proc Nall Acad Sci USA, 1998, 95(4), pp. 1460-1465, 6 pages.
[cited by applicant]
SantaLucia, Jr., “A unified view of polymer, dumbbell, and oligonucleotide DNA nearest-neighbor thermodynamics,” Proc Natl Acad Sci USA, Feb. 17, 1998, 95(4):1460-1465.
[cited by applicant]
Seth, PP et al., “Synthesis and Biophysical Evaluation of 2′,4′-Constrained 2′O-Methoxyethyl and 2′,4′-Constrained 2′ O-Ethyl Nucleic Acid Analogues,” J. Org. Chem., 2010, vol. 75, No. 5, pp. 1569-1581, 7 pages.
[cited by applicant]
Sette, A et al., “The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes,” Journal of Immunology, 1994, pp. 5586-5592, 7 pages.
[cited by applicant]
Chilean Patent Application No. 201802570, abstract, 3 pages.
[cited by applicant]
Caruthers, MH et al., “Chemical Synthesis of Deoxyoligonucleotides by the Phosphoramidite Method,” Methods in Enzymology, 1987, vol. 154:15, pp. 287-313, 27 pages.
[cited by applicant]
Sugimoto, N. et al., “Thermodynamic Parameters to Predict Stability of RNA/DNA Hybrid Duplexes,” Biochemistry, 1995, vol. 34(35), pp. 11211-11216, 6 pages.
[cited by applicant]
Tupin E et al., “Activation of Natural Killer T Cells by Glycolipids,” Methods in Enzymol., 2006, vol. 417, pp. 185-201, 17 pages.
[cited by applicant]
Uhlmann E, “Recent advances in the medicinal chemistry of antisense olignonucleotides,” Current Opinion in Drug Development, 2000, vol. 3(2), pp. 203-213, 12 pages.
[cited by applicant]
Vester B et al., “Chemically modified oligonucleotides with efficient RNase H response,” Bioorganic & Medicinal chemistry Letters, 2008, vol. 18, pp. 2296-2300, 5 pages.
[cited by applicant]
Wykes et al., “Malaria drives T cells to exhaustion,” Front Microbiol, May 27, 2014, 5:249.
[cited by applicant]
Breton et al., “siRNA knockdown, 11 of PD-L1 and PD-L2 in monocyte-derived dendrilic cells only modestly improves proliferative responses to Gag by CD8(+) T cells from HIV-1-infected individuals.”, J Clin Immunol, (Sep.…
[cited by applicant]
Yang et al., “A mouse model for HBV immunotolerance and immunotherapy,” Cellular & Molecular Immunology, Jan. 2014, 11(1):71-78.
[cited by applicant]
Biessen et al., “Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo,” Biochem J., Jun. 15, 1999, 340 (pt 3):783-792.
[cited by applicant]
Biessen et al., “Synthesis of Cluster Galactosides with High Affinity for the Hepatic AsialoglycoproteinReceptor,” J. Med. Chem., Apr. 28, 1995, 38(9):1538-1546.
[cited by applicant]
Bertoletti et al., “Different Cytokine Profiles of Intrahepatic T Cells in Chronic Hepatitis B and Hepatitis C Vims Infections,” Gastroenterology, Jan. 1997;112(1):193-199.
[cited by applicant]
Bergstrom DE, “Unnatural nucleosides with unusual base pairing properties”, Current Protocols in Nucleic Acid Chemistry, 2009, Suppl. 37 1.4.1, 32 pgs.
[cited by applicant]
Berge etal, Pharmaceutical Salts, Journal of Pharmaceutical Sciences, 1977, vol. 66, No. 1, pp. 1-19 (Year: 1977).
[cited by applicant]
Barber et al., “Restoring function in exhausted CDS T cells during chronic viral infection,” Nature, Feb. 9, 2006, 439:682-687, 13 pages.
[cited by applicant]
Asseline, et al., “Nucleic acid-binding molecules with high affinity and base sequence specificity: Intercalating agents covalently linked to oligodeoxynucleotides,” Proc. Natl. Acad. Sci. USA, Jun. 1984, 81:3297-3301.
[cited by applicant]
“International Search Report and Written Opinion of the International Searching Authority,” issued in connection with Int'l Appl. No. PCT/EP2017/055925, dated Jun. 8, 2017 (12 pages).
[cited by applicant]
Breton, G. SiRNA knockdown of PD-L1 and PD-L2 in monocyte-derived dendritic cells only modestly improves proliferative responses to Gag by CD8+ T Cells from HIV-1 infected individuals, J Clin Immunol, 2009, 29(5), pp. 6…
[cited by applicant]
Mazanet, M. M. et al. B7-H1 is Expressed by Human Endothelial Cells and Suppresses T Cell Cytokine Synthesis, J Immunology, 2002, vol. 169, No. 7, pp. 3581-3588.
[cited by applicant]
Bhadra et al., “Control of Toxoplasma reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1-PDL-1 blockade,” Proc Natl Acad Sci USA, May 31, 2011, 108(22):9196-9201.
[cited by applicant]
Bhadra et al., “PD-1-mediated attrition of polyfunctional memory CD8+ T cells in chronic toxoplasma infection,” JInfectDis, Jul. 2012, 206(1):125-134.
[cited by applicant]
Dion et al., “Adeno-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DRI molecules,” J Virol, May 2013, 87(10):5554-5563.
[cited by applicant]
Dolina et al., “Lipidoid Nanoparticles Containing PD-LI siRNA Delivered In Vivo Enter Kupffer Cells and Enhance NK and CD8+ T Cell-mediated Hepatic Antiviral Immunity,” Molecular Therapy-Nucleic Acids, Feb. 19, 2013, 2:…
[cited by applicant]
Esch et al., “Programmed death 1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte function,” J Immunol, Dec. 1, 2013, 191(11):5542-5550.
[cited by applicant]
Freeman et al., “A new therapeutic strategy for malaria: targeting T cell exhaustion,” Nat Immunol, Jan. 19, 2012, 13(2):113-115.
[cited by applicant]
Joshi et al., “B7-HI Blockade Increases Survival of Dysfunctional CD8+ T Cells and Confers Protection against Leishmania donovani Infections,” PLoS Pathog, May 15, 2009, 5(5):e1000431.
[cited by applicant]
Kapoor et al., “Strategies to eliminate HBV infection,” Future Virol, 2014, 9(6):565-585.
[cited by applicant]
Liang et al., “PD-LI and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis,” Eur J Immunol, Jan. 2006, 36(1):58-64.
[cited by applicant]
Loirat et al., “Multiepitopic HLA-A*020 !-restricted immune response against hepatitis B surface antigen after DNA-based immunization,” J Immunol, Oct. 15, 2000, 165(8):4748-4755.
[cited by applicant]
Maier et al., “PD-I:PD-LI interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver,” J. Immunol., Mar. 1, 2007, 178(5):2714-2720.
[cited by applicant]
Michel et al., “DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans,” Proc Natl Acad Sci USA, Jun. 6, 1995, 92(12):5307-5311.
[cited by applicant]
Mizukoshi et al., “Cellular immune responses to the hepatitis B virus polymerase,” J Immunol, Nov. 1, 2004, 173(9):5863-5871.
[cited by applicant]
Rehermann et al., “The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis,” J Exp Med, Mar. 1, 1995, 181(3):1047-1058.
[cited by applicant]
Salem et al., “Programmed death-1/programmed death-LI signaling pathway and its blockade in hepatitis C virus immunotherapy,” World J Hepatol, Oct. 18, 2015, 7(23):2449-2458.
[cited by applicant]
Yang N et al., “HPMA polymer-based site-specific delivery of oligonucleotides to hepatic stellate cells,” Bioconjug Chem, Feb. 2009, 20(2):213-221.
[cited by applicant]
Yi et al., “T-cell exhaustion: characteristics, causes and conversion,” Immunology, Apr. 2010, 129(4):474-481.
[cited by applicant]
Yu R Z et al., “Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice,” Molecular Therapy Nucleic Acids, Jan. 2016, vol. 5, E317.
[cited by applicant]
Prakash T P et al., “Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice,” Nucleic Acids Research, 2014, vol. 42, issue 13, pp. 8796-…
[cited by applicant]
European Patent Application No. 15194811.4 filed Nov. 16, 2015,44 pgs.
[cited by applicant]
Biessen et al., Receptro-dependent cell specific delivery of antisense oligonucleotides, Developments in Cardovascular Medicine, 1999, vol. 214, pp. 285-300.
[cited by applicant]
GenBankAccession No. NM_014143, “
[cited by applicant]
GenBank Accession No. NM_021893, “Mus musculus CD274 antigen (Cd274), mRNA,” Feb. 15, 2015, 8 pages.
[cited by applicant]
GenBank Accession No. XM_005581779, “Predicted: Macaca fascicularis CD274 molecule (CD274), transcript variant XI, mRNA,” Sep. 19, 2013, 5 pages.
[cited by applicant]
Gennaro A R et al., Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pa., 17th ed., 1985.
[cited by applicant]
Glen Research Catalogue No. 10-1920-xx downloaded Mar. 21, 2018.
[cited by applicant]
Glen Research Catalogue No. 10-1922-xx downloaded Mar. 21, 2018.
[cited by applicant]
Glen Research Catalogue No. 10-1925-xx downloaded Mar. 21, 2018.
[cited by applicant]
Hangeland et al., “Cell-type specific and ligand specific enhancement of cellular uptake of oligodeoxynucleoside methylphosphonates covalently linked with a neoglycopeptide, YEE(ah-GalNAc)3,” Bioconjug Chem., Nov.-Dec. …
[cited by applicant]
Enquiry under Substantive Examination issued in Russian Patent Application No. 2018134379, mailed Jun. 22, 2020, 8 pgs.
[cited by applicant]
Maier et al., “Synthesis of antisense oligonucleotides conjugated to a multivalent carbohydrate cluster for cellular targeting,” Bioconjug Chem, Jan.-Feb. 2003, 14(1):18-29.
[cited by applicant]
Manoharan, M., Designer Antisense Oligonucleotides: Conjugation Chemistry and Functionality Placement, in Crooke S T and Lebleu B (eds) Antisense Research and Applications, CRC Press, Boca Raton, Fla., 1993, pp. 303-350.
[cited by applicant]
Manoharan, M., “Oligonucleotide Conjugates in Antisense Technology,” Antisense Drug Technology, Marcel Dekker, Inc., 2001, Ch. 16, pp. 391-469, 81 pages.
[cited by applicant]
Manoharan: Antisense Drug Technology, Principles, Strategies, and Applications, Marcel Dekker Inc, 2001.
[cited by applicant]
Matsuda S et al., “siRNA Conjugates carring sequentially assembled trivalent N-Acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes,” ACS Chem Biol 2015, vol. 10, No. 5, pp.…
[cited by applicant]
Notice of Allowance issued in Korean Patent Application No. 10-2018-7026546, mailed Jun. 20, 2021, 3 pgs.
[cited by applicant]
Office Action issued in Argentine Patent Application No. 20170100626 on Oct. 7, 2020, 5 pgs.
[cited by applicant]
Office Action issued in Russian Patent Application No. 2018134379, mailed Jun. 23, 2020, 6 pgs (English Translation).
[cited by applicant]
Office Action received for Taiwan Patent Application No. 109135755, mailed on Oct. 25, 2021, 6 pages (3 pages of English Translation and 3 pages of original document).
[cited by applicant]
Xu et al., “Effective small interfering RNAs and phosphorothioate antisense DNAs have different preferences for target sites in the luciferase mRNAs,” Biochem. Biophys. Res. Comm., Jul. 4, 2003, 306(3):712-717.
[cited by applicant]
Zatsepin et al., “Synthesis and applications of oligonucleotide-carbohydrate conjugates,” Chem Biodivers, Oct. 2004, 1(10): 1401-1417.
[cited by applicant]
Chilean application No. CL202001126 filed Apr. 28, 2020, pp. 1-683.
[cited by applicant]
Chilean application No. 17. CL202001127 filed Apr. 28, 2020, pp. 1-682.
[cited by applicant]